Jack W. Singer

Hematology | Oncology
325 9th Ave
Seattle, WA 98104

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Corrigendum to "Assessing cardiac safety in oncology drug development" [Am Heart J 214 (2019) 125-133].

Corrigendum to "Assessing cardiac safety in oncology drug development" [Am Heart J 214 (2019) 125-133].

Journal: American heart journal
Published: December 07, 2019

Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306).

Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306).

Journal: British journal of haematology
Published: June 27, 2019

Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.

Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.

Journal: PloS one
Published: May 23, 2019

Assessing cardiac safety in oncology drug development.

Assessing cardiac safety in oncology drug development.

Journal: American heart journal
Published: April 16, 2019

Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis.

Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis.

Journal: Leukemia & lymphoma
Published: September 21, 2018

Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy.

Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy.

Journal: Oncotarget
Published: July 15, 2018

Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis.

Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis.

Journal: Journal of experimental pharmacology
Published: May 23, 2018

Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial.

Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial.

Journal: Clinical drug investigation
Published: March 23, 2018

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.

Journal: JAMA oncology
Published: March 10, 2018

Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.

Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: February 01, 2018

Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.

Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.

Journal: Leukemia
Published: September 11, 2017

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.

Journal: Journal of hematology & oncology
Published: November 11, 2016
Showing 1-12 of 23

Last Updated: 09/26/2026